Methoxsalen
- Generic Name
- Methoxsalen
- Brand Names
- Oxsoralen, Uvadex
- Drug Type
- Small Molecule
- Chemical Formula
- C12H8O4
- CAS Number
- 298-81-7
- Unique Ingredient Identifier
- U4VJ29L7BQ
- Background
A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA adducts in the presence of ultraviolet A irradiation.
- Indication
For the treatment of psoriasis and vitiligo
- Associated Conditions
- Cutaneous T-Cell Lymphoma (CTCL), Refractory Cutaneous T-cell Lymphoma, Vitiligo, Idiopathic Vitiligo, Severe Psoriasis
Extracorporeal Photopheresis (ECP) With Methoxsalen for Chronic Graft Versus Host Disease (cGVHD)
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- Drug: Standard of Care
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2020-02-19
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 60
- Registration Number
- NCT01380535
- Locations
- 🇺🇸
Medical City Dallas Hospital,Transplant center, Dallas, Texas, United States
🇺🇸Parkland Memorial Hospital, Dallas, Texas, United States
🇮🇹A.O.U. Policlinico- Vittorio Emanuele, Catania, Italy
Extracorporal Photopheresis Pilot Study
- Conditions
- Hematological Malignancies
- Interventions
- Procedure: Extracoporal Photopheresis (ECP)
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2013-04-24
- Lead Sponsor
- Hospices Civils de Lyon
- Target Recruit Count
- 20
- Registration Number
- NCT00930566
- Locations
- 🇫🇷
Centre de Santé - Etablissement Français du Sang (EFS), Lyon, France
🇫🇷Hôpital Edouard Herriot, Service d'Hématologie, Lyon, France
Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell Transplant
- Conditions
- Graft Versus Host Disease
- Interventions
- Procedure: stem cell transplant
- First Posted Date
- 2008-03-20
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT00639717
- Locations
- 🇺🇸
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease
- Conditions
- Crohn's Disease
- Interventions
- Procedure: Extracorporeal Photopheresis
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 25
- Registration Number
- NCT00221026
- Locations
- 🇺🇸
Morristown Memorial Hospital, Morristown, New Jersey, United States
🇧🇪Hospital Erasme/ULB, Brussels, Belgium
🇩🇪Universitat St Josef, Bochum, Germany
Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 86
- Registration Number
- NCT00221000
- Locations
- 🇺🇸
Clinical Pharmacology Study Group, Worchester, Massachusetts, United States
🇮🇹Universita de Genova - Ospedale S. Martino, Genova, Italy
🇺🇸Carolina Arthritis Associates, Wilmington, North Carolina, United States
Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease
- Conditions
- Crohn Disease
- First Posted Date
- 2003-03-11
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 10
- Registration Number
- NCT00056355
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease
- Conditions
- Graft-versus-Host Disease
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 60
- Registration Number
- NCT00054600
- Locations
- 🇺🇸
Tufts New England Medical Center, Boston, Massachusetts, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
🇺🇸Kansas City Cancer Center, Kansas City, Missouri, United States
Safety and Efficacy Study of Photopheresis Plus Standard Therapy to Treat Chronic Graft-versus-Host Disease
- Conditions
- Graft-versus-Host Disease
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Mallinckrodt
- Target Recruit Count
- 72
- Registration Number
- NCT00054613
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸University of Nebraska, Omaha, Nebraska, United States
🇹🇷Ankara University Medical School, Altındağ, Ankara, Turkey
Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma
- Conditions
- Lymphoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Millennix
- Registration Number
- NCT00030589
- Locations
- 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸University of Colorado Health Science Center, Aurora, Colorado, United States
The Therakos UVAR Photopheresis System in the Treatment of AIDS-Related Complex
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Mallinckrodt
- Registration Number
- NCT00002011
- Locations
- 🇺🇸
Morristown Memorial Hosp, Morristown, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.